RetroSense Therapeutics to Present at the 8th Ocular Diseases Drug Discovery Conference

ByConnor Hodde

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD).  RetroSense is developing optogenetic approaches to partial vision restoration in retinitis pigmentosa and potentially dry age-related macular degeneration.

Read the entire article here.

Similar Posts

Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research

ByConnor Hodde

Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research.  The research found that RhopressaTM suppressed the activity of profibrotic proteins – TGF-beta 2 and…

Quinolones Tied to Detached Retina

ByConnor Hodde

Among patients who visited an ophthalmologist over an 8-year period, those with a current prescription for a fluoroquinolone were 4.5 times more likely to have a retinal detachment…The mechanism underlying the association is unknown but is presumed to be related to the destructive effects of fluoroquinolones on collagen and connective tissue. http://www.medpagetoday.com/Ophthalmology/GeneralOphthalmology/32011

Proteomic Studies of Age-Related Ocular Diseases

ByConnor Hodde

A Cleveland Clinic lab has found evidence to support the theory that age-related macular degeneration (AMD) is an inflammatory disease with varying ways to progress to advanced dry and wet AMD.  Focusing on proteomic studies to discover biomarkers and molecular mechanisms of AMD and glaucoma, John W. Crabb, PhD, and his colleagues found many proteins…

Retinal Remodeling And Metabolic Alterations in Human AMD

ByConnor Hodde

Age-related macular degeneration (AMD) is a progressive retinal degeneration resulting in central visual field loss, ultimately causing debilitating blindness.  While many genetic and environmental risk factors are known for AMD, we currently know less about the mechanisms mediating disease progression.  The goal of this article is to illustrate cell types impacted in AMD and demonstrate…

Interim results from clinical trial demonstrate safety of cell-based therapy for retinitis pigmentosa

ByConnor Hodde

Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial.  The cell-based approach taken is intended to rescue sick and dying…

Allergan Makes an Eye-Opening Acquisition

ByConnor Hodde

Global pharmaceutical company Allergan (NYSE:AGN) may have just revealed its plans for the future.  On Aug. 11, the company announced its plan to acquire ForSight Vision5, a privately held biotech.  Allergan will pay $95 million up front and will also pay a milestone payment next year if ForSight’s innovative glaucoma treatment device makes it through the…